Income Statement Presentation 2023
Al submissions for existing products
Projects in phase II and III
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other
Roche
RG3502
RG6264
Phesgo OBI
RG7446
HER2+ BC
Tecentriq¹
NSCLC periadj
RG7446
Gavreto
Tecentriq
RG6396
RG7446
Tumor agnostic (US)
SCCHN adj
RG7446
RG7446
Tecentriq + cabozantinib
RCC adv
RG1594
Ocrevus SC
RMS & PPMS
Tecentriq + paclitaxel
RG7446
TNBC adj
RG7159
RG6413+
Ronapreve**
RG7446
RG6412
SARS-CoV-2 hospitalized (EU) ✓
Tecentriq + Avastin
HCC adj
TNKase
Tecentriq
RG3625
RG7446
RG7159
stroke
ctDNA+ high-risk MIBC
Kadcyla + Tecentriq
HER-2+ eBC high-risk
Tecentriq
High-risk NMIBC
Tecentriq+ lurbinectedin
1l maintenance SCLC
Gazyva
Gazyva
systemic lupus
erythematosus
membranous nephropathy
Actemra
Venclexta
RG1569
RG7601
RG3648
COVID-19 pneumonia✓
r/r MM t(11:14)
Xolair
food allergy
RG7601
Venclexta + azacitidine
1L MDS
Ocrevus higher dose
RG1594
RG7446
Tecentriq SC
Tecentriq + capecitabine
RG7446
all approved indications ✓
or carbo/gem
RG6152
Xofluza
direct transmission
RG7159
Gazyva
lupus nephritis
RG6168
RMS & PPMS
Enspryng
MOG-AD
TNBC
Xofluza
Polivy
RG7596
RG7853
1L DLBCL (US)✓
Alecensa
ALK+ NSCLC adj
RG6152
influenza, pediatric
(0-1 year)
RG6168
Enspryng
myasthenia gravis
Enspryng
RG6168
autoimmune encephalitis
2022
2023
2024
2025 and beyond
Status as of February 2, 2023
✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
1filing timeline based on data from interim analysis
OBI-On-Body Delivery System
**Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with
Regeneron Pharmaceuticals
80View entire presentation